Jason J, Holman R C, Evatt B L
National AIDS Information and Education Program, Centers for Disease Control, Atlanta, GA 30333.
Am J Hematol. 1990 Aug;34(4):262-9. doi: 10.1002/ajh.2830340406.
We evaluated those members of a cohort of 203 hemophilic men providing all necessary information at their 1984 and 1985 evaluations, to determine whether non-heated or less than 80 degrees C dry heat-treated partially purified factor products were associated with 1) the development of AIDS in human immunodeficiency virus (HIV)-infected persons or 2) abnormal immune test results in participants seroconverting or remaining HIV seronegative. We found no relationship between type of factor (VIII vs. IX) (n = 162), frequency of usage (greater than or equal to once a week vs. less than once a week) (n = 141) or yearly doses of non-heated or dry heat-treated partially purified factor (n = 118) and the development of AIDS. Seroconverting participants using partially purified factor products greater than or equal to once a week in 1984 had lower T-helper cell numbers in 1985 than those receiving factor less frequently (median 515 vs. 772/mm3, n = 9), as did those using factor greater than or equal to once a week in 1985 (median 515 vs. 726/mm3, n = 10). A similar relation was seen between 1984 frequency and 1985 T-helper cell numbers of seronegative participants (median 741 vs. 1037/mm3, n = 31). The yearly dose of heat-treated products was not associated with any immune test result or changes in results between years. These findings suggested that frequency of administration of partially purified factor materials may have had an effect upon the immune system, but that total yearly dose did not. Previously used partly purified, dry heat-treated factor concentrates were not associated with the development of AIDS.
我们评估了一组203名血友病男性成员，这些成员在1984年和1985年的评估中提供了所有必要信息，以确定未经加热或低于80摄氏度干热处理的部分纯化因子产品是否与以下情况相关：1）人类免疫缺陷病毒（HIV）感染者中艾滋病的发展；2）血清转化或仍为HIV血清阴性的参与者免疫测试结果异常。我们发现因子类型（VIII与IX）（n = 162）、使用频率（每周大于或等于一次与每周少于一次）（n = 141）或未经加热或干热处理的部分纯化因子的年剂量（n = 118）与艾滋病的发展之间没有关系。1984年每周使用部分纯化因子产品大于或等于一次的血清转化参与者，1985年的辅助性T细胞数量低于使用频率较低的参与者（中位数分别为515与772/mm³，n = 9），1985年每周使用因子大于或等于一次的参与者也是如此（中位数分别为515与726/mm³，n = 10）。在血清阴性参与者的1984年使用频率和1985年辅助性T细胞数量之间也观察到类似关系（中位数分别为741与1037/mm³，n = 31）。热处理产品的年剂量与任何免疫测试结果或不同年份之间的结果变化均无关。这些发现表明，部分纯化因子材料的给药频率可能对免疫系统有影响，但年总剂量则没有。先前使用的部分纯化、干热处理的因子浓缩物与艾滋病的发展无关。
